Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones

Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models

Robert L. Hudkins, James L. Diebold, Ming Tao, Kurt A. Josef, Ho Park Chung, Thelma S. Angeles, Lisa D. Aimone, Jean Husten, Mark A. Ator, Sheryl L. Meyer, Beverly P. Holskin, John T. Durkin, Alexander A. Fedorov, Elena V. Fedorov, Steven C. Almo, Joanne R. Mathiasen, Donna Bozyczko-Coyne, Michael S. Saporito, Richard W. Scott, John P. Mallamo

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R2 and R12 positions led to the identification of the first MLK1 and MLK3 subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and 16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater than 30- to 100-fold selectivity for related family members MLK2 and DLK. Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical efficacy model that was comparable to the first-generation pan-MLK inhibitor 1 (CEP-1347). The MLK1 structure-activity relationships were supported by the first-reported X-ray crystal structure of MLK1 bound with 16.

Original languageEnglish (US)
Pages (from-to)5680-5689
Number of pages10
JournalJournal of Medicinal Chemistry
Volume51
Issue number18
DOIs
StatePublished - Sep 25 2008

Fingerprint

Crystallography
Phosphotransferases
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Structure-Activity Relationship
X-Rays
mitogen-activated protein kinase kinase kinase 11
carbazole
2-methoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol(2,1-a)pyrrolo(3,4-c)carbazole-5-one
2-isopropoxy-12-(2-hydroxyethyl)-13,14-dihydronaphthol(2,1-a)pyrrolo(3,4-c)carbazole-5-one
3,9-bis((ethylthio)methyl)-K-252a
Inhibition (Psychology)

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones : Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. / Hudkins, Robert L.; Diebold, James L.; Tao, Ming; Josef, Kurt A.; Chung, Ho Park; Angeles, Thelma S.; Aimone, Lisa D.; Husten, Jean; Ator, Mark A.; Meyer, Sheryl L.; Holskin, Beverly P.; Durkin, John T.; Fedorov, Alexander A.; Fedorov, Elena V.; Almo, Steven C.; Mathiasen, Joanne R.; Bozyczko-Coyne, Donna; Saporito, Michael S.; Scott, Richard W.; Mallamo, John P.

In: Journal of Medicinal Chemistry, Vol. 51, No. 18, 25.09.2008, p. 5680-5689.

Research output: Contribution to journalArticle

Hudkins, RL, Diebold, JL, Tao, M, Josef, KA, Chung, HP, Angeles, TS, Aimone, LD, Husten, J, Ator, MA, Meyer, SL, Holskin, BP, Durkin, JT, Fedorov, AA, Fedorov, EV, Almo, SC, Mathiasen, JR, Bozyczko-Coyne, D, Saporito, MS, Scott, RW & Mallamo, JP 2008, 'Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models', Journal of Medicinal Chemistry, vol. 51, no. 18, pp. 5680-5689. https://doi.org/10.1021/jm8005838
Hudkins, Robert L. ; Diebold, James L. ; Tao, Ming ; Josef, Kurt A. ; Chung, Ho Park ; Angeles, Thelma S. ; Aimone, Lisa D. ; Husten, Jean ; Ator, Mark A. ; Meyer, Sheryl L. ; Holskin, Beverly P. ; Durkin, John T. ; Fedorov, Alexander A. ; Fedorov, Elena V. ; Almo, Steven C. ; Mathiasen, Joanne R. ; Bozyczko-Coyne, Donna ; Saporito, Michael S. ; Scott, Richard W. ; Mallamo, John P. / Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones : Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models. In: Journal of Medicinal Chemistry. 2008 ; Vol. 51, No. 18. pp. 5680-5689.
@article{7fda3169616e4f45923d7b726acf27ea,
title = "Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones: Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models",
abstract = "The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R2 and R12 positions led to the identification of the first MLK1 and MLK3 subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and 16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater than 30- to 100-fold selectivity for related family members MLK2 and DLK. Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical efficacy model that was comparable to the first-generation pan-MLK inhibitor 1 (CEP-1347). The MLK1 structure-activity relationships were supported by the first-reported X-ray crystal structure of MLK1 bound with 16.",
author = "Hudkins, {Robert L.} and Diebold, {James L.} and Ming Tao and Josef, {Kurt A.} and Chung, {Ho Park} and Angeles, {Thelma S.} and Aimone, {Lisa D.} and Jean Husten and Ator, {Mark A.} and Meyer, {Sheryl L.} and Holskin, {Beverly P.} and Durkin, {John T.} and Fedorov, {Alexander A.} and Fedorov, {Elena V.} and Almo, {Steven C.} and Mathiasen, {Joanne R.} and Donna Bozyczko-Coyne and Saporito, {Michael S.} and Scott, {Richard W.} and Mallamo, {John P.}",
year = "2008",
month = "9",
day = "25",
doi = "10.1021/jm8005838",
language = "English (US)",
volume = "51",
pages = "5680--5689",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "18",

}

TY - JOUR

T1 - Mixed-lineage kinase 1 and mixed-lineage kinase 3 subtype-selective dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-ones

T2 - Optimization, mixed-lineage kinase 1 crystallography, and oral in vivo activity in 1-methyl-4-phenyltetrahydropyridine models

AU - Hudkins, Robert L.

AU - Diebold, James L.

AU - Tao, Ming

AU - Josef, Kurt A.

AU - Chung, Ho Park

AU - Angeles, Thelma S.

AU - Aimone, Lisa D.

AU - Husten, Jean

AU - Ator, Mark A.

AU - Meyer, Sheryl L.

AU - Holskin, Beverly P.

AU - Durkin, John T.

AU - Fedorov, Alexander A.

AU - Fedorov, Elena V.

AU - Almo, Steven C.

AU - Mathiasen, Joanne R.

AU - Bozyczko-Coyne, Donna

AU - Saporito, Michael S.

AU - Scott, Richard W.

AU - Mallamo, John P.

PY - 2008/9/25

Y1 - 2008/9/25

N2 - The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R2 and R12 positions led to the identification of the first MLK1 and MLK3 subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and 16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater than 30- to 100-fold selectivity for related family members MLK2 and DLK. Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical efficacy model that was comparable to the first-generation pan-MLK inhibitor 1 (CEP-1347). The MLK1 structure-activity relationships were supported by the first-reported X-ray crystal structure of MLK1 bound with 16.

AB - The optimization of the dihydronaphthyl[3,4-a]pyrrolo[3,4-c]carbazole-5-one R2 and R12 positions led to the identification of the first MLK1 and MLK3 subtype-selective inhibitors within the MLK family. Compounds 14 (CEP-5104) and 16 (CEP-6331) displayed good potency for MLK1 and MLK3 inhibition with a greater than 30- to 100-fold selectivity for related family members MLK2 and DLK. Compounds 14 and 16 were orally active in vivo in a mouse MPTP biochemical efficacy model that was comparable to the first-generation pan-MLK inhibitor 1 (CEP-1347). The MLK1 structure-activity relationships were supported by the first-reported X-ray crystal structure of MLK1 bound with 16.

UR - http://www.scopus.com/inward/record.url?scp=52449127474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449127474&partnerID=8YFLogxK

U2 - 10.1021/jm8005838

DO - 10.1021/jm8005838

M3 - Article

VL - 51

SP - 5680

EP - 5689

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 18

ER -